RIDDLE&CODE
As of April 1, 2022 , Kai Siefert will take over the managing director position of the blockchain start-up RIDDLE&CODE Energy Solutions GmbH, a joint venture between Wien Energie GmbH, Austria's largest regional energy service provider, and blockchain scale-up RIDDLE&CODE GmbH, also based in Vienna.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220401005045/en/
Kai Siefert has 16 years of professional experience in the energy industry. In his previous position as IT strategist at Wien Energie GmbH, he led a team of software developers and electrical engineers from both joint venture partners to develop blockchain-based digital services and technical solutions for the renewable sector and its distributed energy sources. As a result of this work, the energy tokenisation platform "MyPower" was launched last summer, forming the core product of the young company. Wien Energie GmbH already uses this technology as part of its citizen solar power plant products, where the latest release includes a dynamic incentivisation and remuneration feature.
“Over the past four years, the team has built a digital framework for everyone to participate in decentralised energy markets,” says Siefert. “By using this framework, energy entrepreneurs are able to overcome even the toughest problems, such as asset aggregation and disaggregation, peer-to-peer energy marketing or certificate management. Based on our state-of-the-art tokenisation technology and digital wallets, we provide them with secure, transparent and highly scalable access to value chains of the green economy." As part of his new role, Siefert will focus on the internationalisation of the company and further development of the MyPower platform.
"We have proven the technical and commercial viability of energy tokenization in several "real-market projects" in Vienna. And there is great interest in the solution beyond the Austrian borders. As an immediate success of the whole RIDDLE&CODE Energy Solutions team, I am happy to announce the cooperation with the municipality of Stanz, the Austrian pioneer community of the EU-funded Smart Rural project, which was sealed earlier this week.", says Kai Siefert.
"Kai has done a great job with MyPower, driving strong growth, partnerships, and fantastic product innovation. His track record in the industry speaks for itself as well as his empathy for the challenges enterprises overcome while adopting blockchain technology," said Alexander Koppel, CEO at RIDDLE&CODE GmbH. "We are thrilled to have him as a managing director as we accelerate the next stage of growth."
About RIDDLE&CODE Energy Solutions GmbH
RIDDLE&CODE Energy Solutions GmbH provides blockchain-powered infrastructure that enables resilient, decentralised and fully decarbonized energy markets. With the development of the MyPower platform, the company has demonstrated an effective way for energy players into the machine economy. By tokenizing energy, machines and data, RIDDLE&CODE Energy Solutions GmbH significantly increases the liquidity of distributed assets making them easily accessible to broad investor segments, while their output can be traded and tracked with unprecedented transparency and security.
More information about MyPower: www.riddleandcode.com/energy
View source version on businesswire.com: https://www.businesswire.com/news/home/20220401005045/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
